Phase I dose-finding, safety and tolerability trial of Romiplostim to Improve Platelet Recovery after UCB Transplantation
The world's first umbilical cord blood transplant (UCBT) was performed in 1988,1 and since then UCB has been an increasingly used source of hematopoietic stem cells for allogeneic transplantation. UCBT has several advantages over other stem cell sources including rapid availability, low risk of transmission of infections, less strict HLA matching requirements, low risk of graft-versus- host disease (GVHD), no risk for the donor and lack of donor attrition.2,3 Two major limitations to the successful use of UCBT, however, include delayed hematopoietic recovery and slow immune reconstitution,3,4 with several clinical studies ...
Source: Biology of Blood and Marrow Transplantation - March 1, 2021 Category: Hematology Authors: Georgios E. Christakopoulos, Todd E. DeFor, Stefanie Hage, John E. Wagner, Michael A. Linden, Claudio Brunstein, Nelli Bejanyan, Michael R. Verneris, Angela R. Smith Source Type: research

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report
Preventing chronic graft versus host disease (GVHD) remains challenging because the unique cellular and molecular pathways that incite chronic GVHD are poorly understood. One major point of intervention for potential prevention of chronic GVHD occurs at the time of transplantation when acute donor anti-recipient immune responses first set the events in motion that result in chronic GVHD. After transplantation, additional insults causing tissue injury can incite aberrant immune responses and loss of tolerance further contributing to chronic GVHD. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 1, 2021 Category: Hematology Authors: Kirsten M. Williams, Yoshihiro Inamoto, Annie Im, Betty Hamilton, John Koreth, Mukta Arora, Iskra Pusic, Jaqueline W. Mays, Paul A. Carpenter, Leo Luznik, Pavan Reddy, Jerome Ritz, Hildegard Greinix, Sophie Paczesny, Bruce R. Blazar, Joseph Pidala, Corey Source Type: research

Early T-cell precursor acute lymphoblastic leukemia and T/myeloid mixed phenotype acute leukemia possess overlapping characteristics and both benefit from CAG-like regimens and allogeneic hematopoietic stem cell transplantation
In the World Health Organization (WHO) classification, early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) and T/myeloid mixed phenotype acute leukemia (T/M-MPAL) are classified as distinct entities. The most immature intrathymic T cell progenitors retain myeloid characteristics, and early T cell progenitors can function as the cell of origin of T/M-MPAL.1-3 In clinical practice, ETP-ALL and T/M-MPAL are closely related entities because they have similar immunophenotypes and genomic alterations,4,5 as well as significantly worse outcomes than other classes of T-cell acute lymphoblastic leukemia (T-ALL). (Source: ...
Source: Biology of Blood and Marrow Transplantation - February 27, 2021 Category: Hematology Authors: Sining Liu, Qingya Cui, Haiping Dai, Baoquan Song, Wei Cui, Shengli Xue, Huiying Qiu, Miao Miao, Zhengming Jin, Caixia Li, Chengcheng Fu, Ying Wang, Aining Sun, Suning Chen, Xiaming Zhu, Depei Wu, Xiaowen Tang Source Type: research

Gut microbiota dysbiosis associated with persistent fatigue in hematopoietic cell transplantation survivors
: Fatigue is one of the most prevalent and distressing complications among hematopoietic stem cell transplant (HCT) survivors, negatively affecting physical, social, and emotional domains of quality of life. Chronic systemic inflammation has been linked to alterations in nervous system activity and initiation of distressing symptoms such as fatigue. Damage to gut mucosa due to alteration in gut microbiota (GM) composition and microbial translocation has been shown to increase systemic pro-inflammatory cytokines. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 26, 2021 Category: Hematology Authors: Nosha Farhadfar, Raad Z. Gharaibeh, Wendy J. Dahl, Lacey Mead, Rachel Newsome, Vivian IrrizayGatell, Michael T. Weaver, Zeina Al-Mansour, Christian Jobin, Debra Lyon, John R. Wingard, Debra Lynch Kelly Source Type: research

Chances of Finding Matched Unrelated Donors for Saudi Patients in Need of Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is potentially a curative therapy for many malignant and non-malignant hematological disorders [1]. Patients without a related donor can receive stem cells from a matched unrelated donor (MUD). For successful HSCT, the donor and recipient should have optimal human leukocyte antigens (HLAs) matching, including HLA-A, HLA-B, HLA-C and HLA-DRB1 (8/8) [2]. Transplants with a mismatch at one of these loci has been shown to be associated with a higher mortality risk [2,3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 26, 2021 Category: Hematology Authors: Dunia Jawdat, Yasser Almutairi, Zainab Almutairi, Abdullah Almusa, Ali Hajeer Source Type: research

Impact of pre-transplant renal dysfunction on outcomes after allogeneic hematopoietic cell transplantation
This study explores the impact of different degrees of renal dysfunction on HCT outcomes and examines whether utilization of incremental degrees of renal dysfunction based on estimated glomerular filtration rate (eGFR) improve the predictability of the hematopoietic cell transplantation- comorbidity index (HCT-CI). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 26, 2021 Category: Hematology Authors: Nosha Farhadfar, Ajoy Dias, Tao Wang, Caitrin Fretham, Saurabh Chhabra, Hemant S. Murthy, Larisa Broglie, Anita D'Souza, Shahinaz M. Gadalla, Robert Peter Gale, Shahrukh Hashmi, A. Samer Al-Homsi, Gerhard C. Hildebrandt, Peiman Hematti, David Rizzieri, Ly Source Type: research

Myeloablative vs. Reduced Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes —Long Term Follow up of BMT CTN 0901 Clinical Trial
Hematopoietic cell transplantation (HCT) is the only curative option for patients with myelodysplastic syndrome (MDS) and is frequently used as the preferred consolidative strategy in patients with intermediate and adverse risk acute myeloid leukemia (AML). While myeloablative conditioning (MAC) prior to HCT may be curative there is considerable toxicity and treatment-related mortality (TRM). The understanding that the curative potential of HCT is in part due to the graft vs. leukemia effect (GVL) mediated by donor cells led to the development of reduced-intensity conditioning (RIC) regimens with reduced TRM. (Source: Biol...
Source: Biology of Blood and Marrow Transplantation - February 26, 2021 Category: Hematology Authors: Bart L. Scott, Marcelo C. Pasquini, Mingwei Fei, Raphael Fraser, Juan Wu, Steve M. Devine, David L. Porter, Richard T. Maziarz, Erica Warlick, Hugo F. Fernandez, Robert J. Soiffer, Edwin Alyea, Mehdi Hamadani, Asad Bashey, Sergio Giralt, Nancy L. Geller, Source Type: research

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is often the only curative option for both malignant and nonmalignant diseases.1, 2 During the period of immune recovery after allo-HCT, viral infections, which are normally controlled by T-cell immunity, are a major cause of morbidity and mortality.3-6 A recent retrospective study of 404 allo-HCT recipients showed that detection of multiple viruses was common, including BK virus (BKV), cytomegalovirus (CMV), adenovirus (AdV), Epstein –Barr virus (EBV) and human herpesvirus-6 (HHV-6) and demonstrated an association between the cumulative burden of virus ex...
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Joseph McGuirk, Clint Divine, Seung Hyun Moon, Aastha Chandak, Zhiji Zhang, Genovefa A. Papanicolaou Source Type: research

Human herpesvirus-6 infection and calcineurin inhibitor pain syndrome interaction after umbilical cord blood transplant
Dear Editor: (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Gizem Yassa, Ankur Varma, Jacqueline Baptista, Rebecca Myers, Ashley Reimer, Graeme N Forrest, Sunita Nathan, Celalettin Ustun Source Type: research

Use of Prescription Sialagogues for Management of Xerostomia in Chronic Graft-Versus-Host-Disease
Chronic graft-versus-host disease (cGVHD) is a common long-term complication after allogenic hematopoietic cell transplantation (alloHSCT) that affects more than 50% of patients1, with a wide range of manifestations including cutaneous rash, oral lichen planus-like changes, xerostomia, sclerosis, dry eyes, jaundice, restrictive or obstructive lung disorders, and bone marrow suppression1. One of the most commonly affected sites is the oral cavity, with complications ranging from mucosal sensitivity and difficulty swallowing, to an increased risk of oral squamous cell carcinoma2. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Mohammad Mousavian, Herve Sroussi, Alessandro Villa, Corey Cutler, Nathaniel Treister Source Type: research

Favorable outcomes after single cord blood transplantation for patients with high-risk hematological diseases; a single institute retrospective analysis
Hematopoietic stem cell transplantation (HSCT) is a potentially curative strategy for a wide variety of hematological diseases. With the expansion of donor sources, unrelated cord blood (UCB) and haploidentical transplantations, especially those with post-transplant cyclophosphamide (Haplo-PTCY), have been used as alternatives when matched sibling donors (MSDs) and matched unrelated donors (MUDs) are unavailable1, 2. In particular, UCB has become an established source for HSCT because of its widespread availability, rapid accessibility, increased tolerance to human leukocyte antigen (HLA) mismatches, and decreased incidenc...
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Fumiya Wada, Junya Kanda, Mizuki Watanabe, Yasuyuki Arai, Masakatsu Hishizawa, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo Source Type: research

CD52/GPI-negative T-cells are enriched for alloreactive specificity and predict acute GvHD after stem cell transplantation.
Allogeneic haemopoietic stem cell transplantation (HSCT) is an effective treatment for many patients with haematological malignancy and relies substantially on a ‘graft versus leukaemia’ (GvL) effect mediated by the donor immune system [1,2]. GvL is believed to be mediated predominantly by allogeneic T cell recognition of minor histocompatibility antigens expressed by host haemopoietic cells but the alloreactive response can also mediate graft versus hos t disease (GvHD) through recognition of peptides on other tissues [3,4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Francesca A. Kinsella, Charlotte. F. Inman, Wayne Croft, Jianmin Zuo, Hayden Pearce, Sara Barbieri, Charles Craddock, Ram Malladi, Paul Moss Source Type: research

Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on Anti-Microbial Management in Adults with Hematological Malignancies and Transplant Recipients with Suspected Infections
Infections are a leading cause of morbidity and mortality in hematologic malignancies (HM) and hematopoietic stem cell transplant recipients (SCT)1 –3. It has been suggested that bacteremia occurs in 10% to 25% of patients with febrile neutropenia and can be difficult to diagnose via traditional blood cultures and fluid analysis4. Despite fungal prophylaxis, invasive fungal infections (IFI) still occur in approximately 3.5% of patients causin g considerable morbidity and mortality5,6. IFI's often require tissue biopsies and as a result are challenging to diagnose in allogeneic SCT patients or recipients of intensive ...
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: James Yu, Juan D. Diaz, Steven C. Goldstein, Rushang D. Patel, Juan C. Varela, Caralyn Reyenga, Megan Smith, Tori Smith, Jason Balls, Sarfraz Ahmad, Shahram Mori Tags: Regular Manuscript (Original Research) Source Type: research

Utilization of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Autologous stem cell transplant (ASCT) is a standard of care treatment for eligible patients with multiple myeloma (MM).1 Patients typically receive induction therapy with chemotherapy regimens consisting of immunomodulatory agents, proteasome inhibitors, and anti-CD38 monoclonal antibodies.1,2 Consolidative ASCT after induction therapy has been shown to improve progression free survival,1,3 with some studies also showing an overall survival (OS) benefit.4 –11 Most institutional and consensus guidelines recommend that at time of first ASCT, enough hematopoietic stem cells (HSC) should be collected to perform two stem...
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Emily C. Liang, Lori S. Muffly, Parveen Shiraz, Judith A. Shizuru, Laura Johnston, Sally Arai, Matthew J. Frank, Wen-Kai Weng, Robert Lowsky, Andrew Rezvani, Everett H. Meyer, Robert Negrin, David B. Miklos, Surbhi Sidana Source Type: research

Immunity and vaccination against measles, mumps and rubella in adult allogeneic hematopoietic stem cell transplantation recipients
Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been widely used over the past 40 years as a curative therapy for high-risk hematological diseases, and therefore the number of long-term survivors after allo-HCT has steadily increased. Some studies have reported that the risk of mortality from infection in long-term survivors was significantly higher than that in the general population because of delayed immune reconstitution or the presence of chronic graft-versus-host disease (GVHD) [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Koji Kawamura, Hidenori Wada, Hideki Nakasone, Yu Akahoshi, Shunto Kawamura, Junko Takeshita, Nozomu Yoshino, Yukiko Misaki, Kazuki Yoshimura, Ayumi Gomyo, Masaharu Tamaki, Machiko Kusuda, Kazuaki Kameda, Miki Sato, Aki Tanihara, Shun-ichi Kimura, Shinich Source Type: research

Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Post-transplant outcomes of IDH-mutated acute myeloid leukemia
Acute myeloid leukemia (AML) is a lethal hematologic disease characterized by the clonal expansion of malignant myeloid progenitor cells. For many patients, particularly those with poor-risk disease, allogeneic hematopoietic cell transplant (HCT) is a potentially curative post-remission treatment modality1. However, relapse of AML remains the major cause of treatment failure following allogeneic HCT2, 3. For all adult AML patients receiving an allogeneic HCT in the last decade, the 3-year overall-survival is 49% ± 1% according to the Center for International Blood and Marrow Transplant Research (CIBMTR)3. (Source: B...
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: Evan C. Chen, Shuli Li, Ann-Kathrin Eisfeld, Marlise R. Luskin, Alice Mims, Daniel Jones, Joseph H. Antin, Corey S. Cutler, John Koreth, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Areej El-Jawahri, Steven L. McAfee, Zachariah DeFilipp, Robert J. Soiff Source Type: research

Association between Baseline Patient-reported Outcomes and Complications of Hematopoietic Stem Cell Transplantation (HCT)
Autologous and allogeneic hematopoietic cell transplantation (HCT) are potentially curative treatments for many patients with hematologic malignancies or severe blood disorders.1 However, HCT is a complex process that includes a prolonged hospitalization followed by an arduous recovery period due to social isolation, substantial toxicities, and secondary infections.2 Health care utilization is often intensive, with 30-40% of patients re-hospitalized for significant complications in the first 100 days post-HCT. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 25, 2021 Category: Hematology Authors: P. Connor Johnson, Sunil Bhatt, Matthew J. Reynolds, Tejaswini M. Dhawale, Nneka Ufere, Annemarie D. Jagielo, Mitchell W. Lavoie, Carlisle E.W. Topping, Madison A. Clay, Julia Rice, Alisha Yi, Zachariah DeFilipp, Yi-Bin Chen, Areej El-Jawahri Source Type: research

Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Pre-Sensitization Model: “Radioimmunotherapy to overcome transfusion-induced sensitization”
Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment option for patients with serious, non-malignant blood disorders including aplastic anemia and hemoglobinopathies. Rejection of the allogeneic graft has been a significant complication especially in heavily transfused patients, with rejection probabilities in the range of 35-60% in the earliest transplant series. Rejections were seen despite the use of human leukocyte antigen (HLA)-identical sibling donors and were attributed to sensitization to minor non-HLA antigens via transfusions1. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 24, 2021 Category: Hematology Authors: Aya Nakaya, Huiying Qiu, Erlinda B. Santos, Donald K. Hamlin, D. Scott Wilbur, Rainer Storb, Brenda M. Sandmaier Source Type: research

Haploidentical peripheral stem cell transplantation for young patients with severe aplastic anemia using post-transplant cyclophosphamide and methotrexate
Severe aplastic anemia (SAA) is a serious immune-mediated hematopoietic stem cell disorder that presents with a hypocellular marrow and pancytopenia [1,2]. Successful allogeneic hematopoietic stem cell transplantation (HSCT) overcomes the critical comorbidities of SAA and virtually eliminates the risk of relapse and secondary clonal disorders [2]. Recent improvements in HSCT suggest the possibility of matched unrelated donors (MUDs) as alternative first-line treatment in the absence of matched related donors (MRDs) [3-5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 18, 2021 Category: Hematology Authors: Kaitai Yang, Susu Gong, Tiebin Jiang, Xinquan Liang, Jian Hu, Ping Zhu, Lin Nie, Yajing Xu, Bin Fu, Bone Marrow Failure Working Group (BMFWG) of Hunan Province Source Type: research

Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Pilot Study
Hematopoietic cell transplantation (HCT) is a well-established and potentially curative treatment that is associated with short- and long-term challenges. Patients commonly experience a decline in physical fitness during their admission and recovery that affects their quality of life.1,2 Prolonged hospitalization increases the risk of immobility-associated complications and health care cost.3 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 18, 2021 Category: Hematology Authors: Najla El Jurdi, Nora Nock, Pingfu Fu, Shufen Cao, Joel M Cotton, Naveed Ali, Gayathri Ravi, Raisa Pinto, Erin Galloway, Samantha Kolke, Brenda Cooper, Benjamin Tomlinson, Ehsan Malek, Colleen Lance, Merle J Kolk, Nicole Ferrari, Richard Lee, Marcos de Lim Source Type: research

Colonization with Gastrointestinal Pathogens Prior to Hematopoietic Cell Transplantation and Associated Clinical Implications
Diarrhea is a common complication following hematopoietic cell transplantation (HCT), occurring in 76-91% of transplant recipients [1]. The etiologies of diarrhea in the early post-transplant period include infectious causes, chemotherapy-associated mucosal inflammation, side effects from other medications, and acute graft-versus-host disease (GVHD) [2]. Approximately 40% of HCT recipients with diarrhea have infectious etiologies and Clostridioides difficile infection (CDI) is the most common [3, 4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 17, 2021 Category: Hematology Authors: Jeffrey Kubiak, Emily Davidson, Rosemary Soave, Rosy Priya Kodiyanplakkal, Amy Robertson, Koen van Besien, Tsiporah B. Shore, John R. Lee, Lars F. Westblade, Michael J. Satlin Source Type: research

Late Kidney Morbidity and Mortality in Hematopoietic Cell Transplant Survivors
Hematopoietic cell transplantation (HCT) is increasingly used as a curative therapy for patients with certain high-risk malignancies, with over 500,000 HCT survivors expected to be living in the United States by the year 2030.[1] As more patients become long-term survivors, characterization of their health outcomes is critical to support their healthcare needs given the high prevalence of late complications.[1-4] HCT survivors have greater rates of hospitalization and all-cause mortality compared with non-HCT cancer survivors, while both groups experience higher morbidity and mortality compared with the general population....
Source: Biology of Blood and Marrow Transplantation - February 17, 2021 Category: Hematology Authors: Natalie L. Wu, Sangeeta Hingorani, Kara L. Cushing-Haugen, Stephanie J. Lee, Eric J. Chow Source Type: research

Cellular therapy during COVID-19: Lessons learned and preparing for subsequent waves
An evidence-based triage plan for cellular therapy distribution is critical in the face of emerging constraints on healthcare resources. We evaluated the impact of treatment delays related to COVID-19 on patients scheduled to undergo hematopoietic cell transplantation (HCT) or chimeric antigen receptor T-cell (CAR-T) therapy at our center. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 14, 2021 Category: Hematology Authors: Mariam T Nawas, Gunjan L. Shah, Darren R. Feldman, Josel D. Ruiz, Elizabeth V. Robilotti, Anoshe A. Aslam, Mary Dundas, Mini Kamboj, Juliet N. Barker, Christina Cho, David J. Chung, Parastoo B. Dahi, Sergio A. Giralt, Boglarka Gyurkocza, Oscar B. Lahoud, Source Type: research

Efficacy and Safety of 1% Progesterone Gel to the Forehead on Ocular Chronic Graft-versus-Host Disease
Chronic graft-versus-host disease (GVHD) is the leading cause of morbidity and mortality late after allogeneic hematopoietic stem cell transplant (allo-HSCT), which affects 30-70% of allo-HSCT survivors, with significant impact on quality of life.1,2 The eye is one of the major target organs affected by GVHD, occurring in greater than 50% of patients with chronic GVHD.3,4 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 13, 2021 Category: Hematology Authors: Zhonghui K. Luo, Edgar A. Domenech-Estarellas, Amy Han, Do Lee, Ram Khatri, Jonathan L. Wahl, Corey Cutler, Philippe Armand, Joseph H. Antin, John Koreth, Mahasweta Gooptu, Edwin P. Alyea, Robert J. Soiffer, Vincent T. Ho Source Type: research

Experience Using ATG with PTCY for GVHD Prophylaxis in Peripheral Blood Haploidentical Stem Cell Transplantation
Haploidentical hematopoietic cell transplant (haploHCT) has emerged as an alternative treatment option for patients without a suitable 10/10 HLA matched donor. Haploidentical donors share a single HLA haplotype with recipients but have the advantage of almost universal and immediate availability of donor stem cells for transplantation1, 2. HaploHCT was originally associated with high rates of graft-versus-host disease (GVHD) and graft rejection3. During the last two decades, multiple strategies have been established to overcome HLA barriers resulting in a significant improvement in haploHCT survival rates4, 5. (Source: Bio...
Source: Biology of Blood and Marrow Transplantation - February 13, 2021 Category: Hematology Authors: Maria Queralt Salas, Eshetu G. Atenafu, Arjun Datt Law, Wilson Lam, Ivan Pasic, Carol Chen, Dennis (Dong Hwan) Kim, Fotios V. Michelis, Armin Gerbitz, Jeffrey Howard Lipton, Jonas Mattsson, Rajat Kumar, Auro Viswabandya Source Type: research

Impact of Cell of Origin Classification on Survival Outcomes After Autologous Transplantation in Relapsed/refractory Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide with distinct biological and clinical heterogeneity. Gene-expression profiling (GEP) has allowed DLBCL to be classified into two molecular prognostic subgroups: germinal center B-cell like (GCB) and activated B-cell like (ABC), based on cell of origin (COO) [1]. In clinical practice, GEP has been replaced by the more readily available immunohistochemistry (IHC). Using an IHC panel composed of CD10, BCL6 and MUM1, the Hans algorithm was developed to classify DLBCL into GCB and non-GCB subtypes [2, 3]. (Source: Biology of Blood an...
Source: Biology of Blood and Marrow Transplantation - February 11, 2021 Category: Hematology Authors: Jacinth Joseph, Fady Hennawy, Mustafa Nooruldeen Abdulrazzaq, Neeraj Saini, Junsheng Ma, Romil D. Patel, Chitra M. Hosing, Amin M. Alousi, Paolo Anderlini, Uday R. Popat, Muzaffar H. Qazilbash, Elizabeth J. Shpall, Samer Srour, Partow Kebriaei, Qaiser Bas Source Type: research

Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in children with high-risk leukemia using a reduced-intensity conditioning regimen and peripheral blood as the stem cell source
Allogeneic hematopoietic stem cell transplantation (HSCT) is the best curative option for children with high-risk acute leukemia. However, only 30% of patients have a compatible familial donor, and for minorities, only one in three have an unrelated matched donor1. This limits the possibility of transplant for these patients, especially in countries with limited resources and access difficulties to unrelated cord blood units or bone marrow donors. Fortunately, a partially compatible (haploidentical) related donor is available in at least 95% of cases2, and the use of cyclophosphamide post-transplantation has allowed the us...
Source: Biology of Blood and Marrow Transplantation - February 11, 2021 Category: Hematology Authors: Ángela Maria Trujillo, Amado J Karduss, Gloria Suarez, Rosendo Pérez, Giovanni Ruiz, Angélica Cardona, Mónica Ramírez, José Betancur Source Type: research

An ATG free conditioning regimen using Fludarabine and Cyclophosphamide is associated with good outcomes in patients undergoing matched related family donor transplants for aplastic anaemia: ATG free fludarabine based conditioning in aplastic anaemia
Allogeneic hematopoietic stem cell transplantation (HSCT) using a matched related donor (MRD) is the treatment of choice for a young patient ( (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 6, 2021 Category: Hematology Authors: Biju George, Sharon Lionel, Sushil Selvarajan, Fouzia N Abubacker, Anu Korula, Anup J Devasia, Uday Kulkarni, Kavitha M Lakshmi, Eunice Sindhuvi, Aby Abraham, Vikram Mathews Source Type: research

Predicting Outcomes following Anti-CD19 CAR T Cell Therapy in Aggressive B Cell Lymphomas
CD19-directed chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of relapsed or refractory (R/R) aggressive B cell non-Hodgkin lymphoma and has led to durable complete response (CR) rates of approximately 30% to 40% [1-4]. Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are the 2 anti-CD19 CAR T cell products currently approved by the Food and Drug Administration (FDA) for patients with R/R diffuse large B cell lymphoma (DLBCL) after receiving 2 or more previous lines of systemic therapy [1,3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Carrie Ho, Jakub Svoboda Source Type: research

Minimal Residual Disease in Acute Myelogenous Leukemia Is Predictive, Unless You Are Over Age 60 and Treated with Decitabine
Assessment of minimal or measurable residual disease (MRD) has emerged as a powerful and predictive tool for outcomes in patients with acute leukemia. There are several methods of measuring MRD, including detection of pathogenic mutations on next-generation genomic profiles and the detection of driver transcripts by real-time quantitative polymerase chain reaction. More commonly, MRD is characterized by highly sensitive multiparameter flow cytometry, which has allowed detection of leukemia cells to a level of 1:104 or 1:106 [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Aleksander Chojecki Source Type: research

Sexuality and fertility related issues in women after allogeneic hematopoietic stem cell transplant
As probability of long term survival reaches 80% in patients who survive two years after allogeneic hematopoietic stem cell transplant (HSCT),1 management of late effects appears as a major concern. Among sequelae of HSCT, hypogonadism and infertility are important issues with a heavy impact on quality of life.2 These complications occur in most patients transplanted after myeloablative conditioning (MAC) regimens,3 but few data exist in the setting of reduced-intensity conditioning (RIC) regimens. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Nathalie Forgeard, Matthieu Jestin, Dominique Vexiau, Florian Chevillon, Elise Ricadat, R égis Peffault de Latour, Marie Robin, Flore Sicre de Fontbrune, Aliénor Xhaard, David Michonneau, Nicolas Boissel, Catherine Poirot, Nathalie Dhédin Source Type: research

Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double-Blind Placebo-Controlled Trial
Prolonged thrombocytopenia occurs in up to 37% of patients after hematopoietic stem cell transplantation (HSCT) and is associated with adverse prognosis and increased risk of bleeding. Eltrombopag, a thrombopoietin receptor agonist, can increase platelet counts in thrombocytopenic patients. We conducted a phase II study, adaptively randomizing patients ≥35 days post-HSCT to receive placebo or eltrombopag if platelet count ≤ 20,000/µL for seven days or platelet transfusion-dependent, and neutrophil count ≥ 1500/µL. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Sairah Ahmed, Qaiser Bashir, Roland Bassett, Man-Yin C. Poon, Ben Valdez, Sergej Konoplev, Amin M. Alousi, Borje S. Andersson, Stefan Ciurea, Chitra Hosing, Roy Jones, Partow Kebriaei, Issa Khouri, Stella Kim, Yago Nieto, Amanda Olson, Betul Oran, Simrit Source Type: research

Predicting Outcomes Following Anti-CD19 CAR T-cell Therapy in Aggressive B-cell Lymphomas
CD19-directed chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of relapsed or refractory (R/R) aggressive B-cell non-Hodgkin lymphoma and has led to durable complete response (CR) rates around 30-40%.1 –4 Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are the two current anti-CD19 CAR T-cell products approved by the Food and Drug Administration (FDA) for patients with R/R diffuse large B cell lymphoma (DLBCL) after two or more prior lines of systemic therapy. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Carrie Ho, Jakub Svoboda Source Type: research

Feasibility and outcomes of a third allogeneic hematopoietic stem cell transplantation: a retrospective analysis from the ALWP of the EBMT
Few therapeutic options are available for patients with acute myeloid or lymphoblastic leukemia (AML/ALL) relapsing after a second allogeneic stem cell transplantation (alloSCT2). In selected patients a third allogeneic stem cell transplantation (alloSCT3) has been used, but no detailed analysis is available so far.The European Society for Blood and Marrow Transplantation (EBMT) registry was screened for patients with acute leukemia (AL) who had undergone alloSCT3 from an identical or alternative donor to treat AL in either hematological relapse or disease persistence after alloSCT2 between 2001 and 2018. (Source: Biology ...
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: A. Rank, C. Peczynski, M. Labopin, M. Stelljes, C. Simand, G. Helbig, J. Finke, S. Santarone, J. Tischer, A. Lange, M. Mistrik, M. Houhou, C. Schmid, A. Nagler, M. Mohty Source Type: research

Cellular Therapies for Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a subtype of B-cell non-Hodgkin lymphoma (NHL) characterized by the presence of t(11;14) (q13;q32) translocation, resulting in overexpression of cyclin D11, 2. MCL commonly presents in the seventh decade of life (median age 65 years) with a heterogeneous clinical presentation2. The 2016 World Health Organization updated classification of the lymphoid neoplasms identifies 2 major MCL clinical entities, namely the classical or conventional MCL (cMCL), and the leukemic non-nodal MCL (nnMCL)3. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Farah Yassine, Jose Sandoval-Sus, Ernesto Ayala, Julio Chavez, Mehdi Hamadani, Mohamed A. Kharfan-Dabaja Source Type: research

MRD in AML is predictive, unless you are over age 60 and treated with decitabine
Assessment of MRD (minimal or measurable residual disease) has emerged as a powerful and predictive tool for outcomes in patients with acute leukemia. There are several methods of measuring MRD including detection of pathogenic mutations on next generation genomic profiles and the detection of driver transcripts by real-time quantitative polymerase chain reaction (PCR). More commonly, MRD is characterized by highly sensitive multiparameter flow cytometry which has allowed detection of leukemia cells to a level of 1:10^4 or 1:10^6. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2021 Category: Hematology Authors: Aleksander Chojecki Source Type: research

Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay
Oropharyngeal mucositis (OPM) is common following conditioning for allogeneic hematopoietic cell transplantation (alloHCT) and results in pain, functional status decline, need for nutritional support, infections, and prolonged length of stay (LOS). Methotrexate (MTX) graft-versus-host disease (GVHD) prophylaxis exacerbates OPM and slows hematopoietic engraftment, which may prolong the LOS. Previous studies have demonstrated reduced OPM and more rapid engraftment when leucovorin (LCV) is added following MTX GVHD prophylaxis, yet this practice is controversial. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 4, 2021 Category: Hematology Authors: Craig W. Freyer, Shannon Gier, Mary E. Moyer, Natasha Berryman, Alison Carulli, Alex Ganetsky, Colleen Timlin, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Shannon McCurdy, Alex Source Type: research

Leucovorin rescue after methotrexate graft-vs-host disease prophylaxis shortens the duration of mucositis, time to neutrophil engraftment, and hospital length of stay
Oropharyngeal mucositis (OPM) is a common and often dose-limiting toxicity of allogeneic hematopoietic transplantation (alloHCT), resulting from chemotherapy or radiation-induced gastrointestinal mucosal toxicity.1 OPM results in pain, inadequate caloric intake, inability to take oral medications, gastrointestinal malabsorption, bleeding, and rarely airway compromise. Patients may require total parenteral nutrition (TPN) and parenteral opioid therapy, often in the form of patient-controlled analgesia (PCA) until recovery from OPM, which typically occurs at the time of neutrophil engraftment. (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - February 4, 2021 Category: Hematology Authors: Craig W. Freyer, Shannon Gier, Mary E. Moyer, Natasha Berryman, Alison Carulli, Alex Ganetsky, Colleen Timlin, Daria V. Babushok, Noelle V. Frey, Saar I. Gill, Elizabeth O. Hexner, Alison W. Loren, James K. Mangan, Mary Ellen Martin, Shannon McCurdy, Alex Source Type: research

Early-Phase Peripheral Blood Eosinophilia Predicts Lower Overall and Non-Relapse Mortality After Single-Unit Cord Blood Transplantation
The objective of this study was to examine the associations between eosinophilia and overall survival, relapse incidence, non-relapse mortality, and acute and chronic GVHD after single-unit CBT for adults. We retrospectively analyzed the data for 225 adult patients who received single-unit CBT at our institute between March 2004 and March 2020. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2021 Category: Hematology Authors: Takaaki Konuma, Maki Monna-Oiwa, Yuta Kaito, Masamichi Isobe, Motohito Okabe, Seiko Kato, Satoshi Takahashi, Arinobu Tojo Source Type: research

Early phase peripheral blood eosinophilia predicts lower overall and non-relapse mortality after single-unit cord blood transplantation
Eosinophils are terminally differentiated granulocytes that exhibit large, pink-stained cytoplasmic secretory granules when stained with the acidic bromide-containing dye eosin. Eosinophils play major roles in tissue repair and homeostasis and in host defense against helminth parasites.1 Eosinophilia is frequently observed during a variety of conditions, such as allergic, infectious, gastrointestinal, rheumatologic, and neoplastic disorders1 as well as post-allogeneic hematopoietic transplantation (HCT). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2021 Category: Hematology Authors: Takaaki Konuma, Maki Monna-Oiwa, Yuta Kaito, Masamichi Isobe, Motohito Okabe, Seiko Kato, Satoshi Takahashi, Arinobu Tojo Source Type: research

Ruxolitinib inhibits IFN γ licensing of human bone marrow derived Mesenchymal Stromal Cells
Ruxolitinib is a small molecule inhibitor of JAK2/JAK1 kinases1. Ruxolitinib was initially approved for the treatment of ABL-negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia and primary myelofibrosis that are caused by the aberrant activation of the JAK-STAT pathway in hematopoietic cells2, 3. Ruxolitinib is also being clinically investigated for treatment of non-myeloproliferative disorders including irritable bowel disease, rheumatoid arthritis, psoriatic skin lesions and Graft versus Host Disease (GVHD)4, 5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2021 Category: Hematology Authors: Molly Mercedes Ryan, Mihir Patel, Keenan Hogan, Ariel Joy Lipat, Rafaela Scandolara, Rahul Das, Charles Bruker, Jacques Galipeau, Raghavan Chinnadurai Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Source Type: research

Officers, Directors & Board Committee Chairs 2021
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Source Type: research

Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Source Type: research

Efficacy and Safety of Betibeglogene Autotemcel (beti-cel; LentiGlobin for β-thalassemia) Gene Therapy in 60 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed for up to 6 Years Post-Infusion
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Suradej Hongeng, Alexis A. Thompson, Janet L. Kwiatkowski, Franco Locatelli, John B. Porter, John Rasko, Marina Cavazzana, Martin G. Sauer, Adrian J. Thrasher, Isabelle Thuret, Ashutosh Lal, Andreas E. Kulozik, Evangelia Yannaki, Manfred Schmidt, Ying Che Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research

Conditioning Regimens Are Associated with Distinct Patterns of Microbiota Injury Independent of Antibiotic Exposure
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Roni Shouval, Antonio Gomes, Chi L. Nguyen, Kate Ann Markey, Anqi Dai, Corrado Zuanelli Brambilla, Ying Taur, Michael Scordo, Sergio A Giralt, Miguel Perales, Marcel R.M. van den Brink, Jonathan U. Peled Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Ryotaro Nakamura, Wael Saber, Michael Martens, Alyssa Ramirez, Bart L. Scott, Betul Oran, Eric Leifer, Roni Tamari, Asmita Mishra, Richard T. Maziarz, Joseph P McGuirk, Peter Westervelt, Sumithira Vasu, Mrinal M. Patnaik, Rammurti T. Kamble, Stephen J. Fo Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research

Interim Analysis (IA) of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients (Pts) with High-Risk Large B Cell Lymphoma (LBCL)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Sattva S. Neelapu, Michael Dickinson, Matthew L. Ulrickson, Olalekan O. Oluwole, Alex F. Herrera, Catherine Thieblemont, Chaitra S Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Yin Yang, Francesca Milletti, Lovely Goyal, Jun Kawashima, Jul Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research

COVID-19 in Hematopoietic Cell Transplant Recipients: A CIBMTR Study
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Akshay Sharma, Neel S. Bhatt, Andrew St. Martin, Muhammad Bilal Abid, Jenni Bloomquist, Roy F. Chemaly, Christopher E. Dandoy, Jordan Gauthier, Lohith Gowda, Miguel A. Perales, Stuart E. Seropian, Bronwen E. Shaw, Eileen E. Tuschl, Amer Zeidan, Marcie L. Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research

High OS, PFS and EFS with Low Rates of Rejection and GVHD after KIR-Favorable abCD3/CD19 Depleted Haploidentical HCT in Children with ALL/AML/MDS: Primary Analysis of the Pediatric Transplantation and Cellular Therapy Consortium ONC1401 Trial
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 31, 2021 Category: Hematology Authors: Hisham Abdel-Azim, Christopher C Dvorak, Nancy J. Bunin, Nahal Lalefar, Eric Anderson, Allyson Flower, Julie-An Talano, Kwang Woo Ahn, Sonali Chaudhury, Carrie Lynn Kitko, Dimitri Monos, Leung Wing, Mike A. Pulsipher Tags: TCT MEETINGS BEST ABSTRACTS Source Type: research